Here are five quick facts:
1. The trial is intended to support the expanded use of MONOVISC to treat pain caused by hip osteoarthritis.
2. MONOVISC is a single injection viscosupplement comprised of non-animal sourced hyaluronic acid.
3. It is currently approved by the FDA to treat pain caused by osteoarthritis of the knee.
4. The study plans to enroll around 560 subjects across 20 investigational sites in the United States, beginning in 2015.
5. The study will be sponsored by DePuy Synthes Mitek Sports Medicine, Anika’s commercial partner and exclusive distributor of MONOVISC in the U.S.
More articles on devices:
Bioness receives Gold Seal of Approval from the Joint Commission
Stryker shares increase by 1.26% this week — 5 facts
K2M co-founder Dr. John Kostuik sells 46k shares: 6 quick facts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
